Linker Information
General Information of This Linker
| Linker ID |
LIN0JEPEI
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
AU2023279443A1, Example A18, Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C55H87N12O21P
|
|||||
| Isosmiles |
CC(C)[C@H](NC([C@@H](NC([C@H](CCCCN(C)C)NC(CCOCCOCCOCCOCCNC([C@@H](N1C(C=CC1=O)=O)CNC(CCP(O)(O)=O)=O)=O)=O)=O)CC(N[C@H]2CCOC2=O)=O)=O)C(N[C@H](C(NC3=CC=C(CO)C=C3)=O)CCCNC(N)=O)=O
|
|||||
| InChI |
InChI=1S/C55H87N12O21P/c1-35(2)48(53(78)63-39(9-7-19-58-55(56)80)49(74)60-37-12-10-36(34-68)11-13-37)65-51(76)41(32-45(71)62-40-16-23-88-54(40)79)64-50(75)38(8-5-6-21-66(3)4)61-44(70)17-22-84-25-27-86-29-30-87-28-26-85-24-20-57-52(77)42(67-46(72)14-15-47(67)73)33-59-43(69)18-31-89(81,82)83/h10-15,35,38-42,48,68H,5-9,16-34H2,1-4H3,(H,57,77)(H,59,69)(H,60,74)(H,61,70)(H,62,71)(H,63,78)(H,64,75)(H,65,76)(H3,56,58,80)(H2,81,82,83)/t38-,39-,40-,41-,42-,48-/m0/s1
|
|||||
| InChIKey |
TWJSPZMBRNDYJH-QQVKLFTPSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1283.338
|
Polar area
|
469.52
|
||
|
Complexity
|
2466.332108
|
xlogp Value
|
-3.7349
|
|||
|
Heavy Count
|
89
|
Rot Bonds
|
45
|
|||
|
Hbond acc
|
20
|
Hbond Donor
|
13
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
AU2023279443A1 Example A18 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 103% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
A mixed solvent of PBS and and Matrigel was used to prepare a cell suspension of 5.0x107 cells / mL. The prepared cell suspension was subcutaneously injected to the right flank region of female BALB/c-nu/nu mice at 0.1 mL per mouse. Individuals having a tumor volume within a range of 50 to 500 mm 3 were selected. test compound at a concentration of 3 mg/kg or the solvent alone was intravenously administered. the tumor volume was measured at Day 0 and Day 21.
Click to Show/Hide
|
||||
| In Vivo Model | NCI-N87 female BALB/c-nu/nu mice model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition rate (%) | > 14% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cell growth inhibition test was carried out on HER2-positive human gastric cancer cell line (NCI-N87), the cells were treated with a test compound or an anti-HER2 antibody (trastuzumab) at a concentration of 100 ng/mL. The cells were cultured for 6 days, then CellTiter-Glo was added and the luminescence amount was measured.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||